Mar 07, 2023 / 02:50PM GMT
Unidentified Analyst
Awesome, well, thank you, Anirvan from Unity for being here at the 43rd Annual Cowen Healthcare Conference. So excited to have you here [because we're excited about your story. So thank you for joining us virtually. So I will turn it to you, Anirvan].
Anirvan Ghosh - Unity Biotechnology, Inc. - CEO
Right. Thanks. I'm pleased to provide an update on our lead program, UBX1325 and our upcoming data readouts in the coming months. Before I get started, I just wanted to remind you that I'll be making forward-looking statements during my presentation today that are summarized over here and detailed in our SEC filings.
At Unity, we are developing a new class of therapeutics called senolytics to target progressive vision loss. The two indications are primarily focused on our diabetic macular edema and age-related macular degeneration. These are two major causes of vision loss globally. And despite being one of the standard of care treatment anti-VEGF, many patients do not get to 2040 or otherwise good vision.
We recently shared Phase 2 data
UNITY Biotechnology Inc at Cowen Health Care Conference Transcript
Mar 07, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers